NIKKEI 225
27,999.96 -249.28 (-0.88%) HANG SENG
20,003.44 -42.33 (-0.21%) CRUDE OIL
90.64 -0.12 (-0.13%) GOLD FUTURES
1,810.90 +5.70 (+0.32%) DOW
32,774.41 -58.13 (-0.18%) BTC-GBP
19,125.01 -789.59 (-3.96%)
CVAC Jan 2023 92.500 call
| Previous close | 12.40 |
| Open | 12.40 |
| Bid | 1.35 |
| Ask | 3.50 |
| Strike | 92.50 |
| Expiry date | 2023-01-20 |
| Day's range | 12.40 - 12.40 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
- Reuters
BioNTech, Pfizer sue CureVac in U.S. over COVID-19 vaccine patent claims
COVID-19 vaccine maker BioNTech said on Tuesday that it and partner Pfizer have filed a complaint with the U.S. District Court in Massachusetts, seeking a judgment that they did not infringe U.S. patents held by rival CureVac. The lawsuit, filed Monday, said CureVac is trying to profit from the success of BioNTech and Pfizer's COVID-19 vaccines after CureVac's efforts to create its own vaccine failed.
- Zacks
Wall Street Analysts Predict a 96% Upside in CureVac N.V. (CVAC): Here's What You Should Know
The mean of analysts' price targets for CureVac N.V. (CVAC) points to a 96.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
- Simply Wall St.
Analysts Expect Breakeven For CureVac N.V. (NASDAQ:CVAC) Before Long
We feel now is a pretty good time to analyse CureVac N.V.'s ( NASDAQ:CVAC ) business as it appears the company may be...
